Roles of the Calcitonin Gene-Related Peptide Family in the Central Nervous System by Hashimoto Hirofumi
Roles of the CGRP family in the CNS44（3）（2017） 239
and pathophysiological effects. The activation of CGRP 
family was inhibited or attenuated by CGRP8-37 and/
or AM22-52, which is used as CGRP and AM antago-
nist, respectively 9）. Afterward, it has been clarified 
that they are regulated by a combination of calcitonin 
receptor （CR） or calcitonin receptor-like receptor 
（CRLR）, and the receptor activity-modifying proteins 
（RAMPs）. CR and CRLR （CR/CRLR） is a G protein-
coupled receptor, and these receptors have unique 
system. CR/CRLR needs the receptor activity-modi-
fied protein for their activation. Three receptor activi-
ty-modified proteins, RAMP1-3, were identified in 
rats and mice 10）. CR/CRLR formed a complex with 
each RAMP and was translocated from endoplasmic 
reticulum to cell membrane 10）. CR/CRLR or RAMPs 
alone were not activated as receptor. Namely, CR/
CRLR cannot translocate to cell membrane and cannot 
be activated without RAMPs11）. CGRP8-37 blocked the 
INTRODUCTION
The calcitonin gene-related peptide （CGRP） family 
is composed of CGRP, adrenomedullin （AM）, AM2, 
AM5 and amylin 1～6）. Their structures are similar, 
each having an internal disulfide bridge with a ring 
and amidated carboxyl terminal （Fig. 1）. Both these 
structural traits are essential for receptor binding and 
subsequent signaling 7,8）. CGRP family is widely dis-
tributed in the peripheral tissues and the central ner-
vous system （CNS） and have various physiological 
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SUMMARY
The calcitonin gene-related peptide （CGRP） family is composed of CGRP, adrenomedullin （AM）, AM2 
（identical to intermedin）, AM5 and amylin. These peptides are widely distributed in peripheral tissues and 
the central nervous system （CNS）. They activate a cAMP-dependent pathway via complexes of calcitonin 
receptor or calcitonin receptor-like receptor and receptor activity-modifying proteins. They are involved in 
several physiological and pathological functions such as water intake, feeding, and modulation of cardiovas-
cular and neuroendocrine systems. Previous studies have shown that a central administration of these neu-
ropeptides activated various areas in the CNS and induced physiological effects. Our previous studies 
showed that centrally administered AM family （AM, AM2 and AM5） induces the expressions of the c-fos 
gene in the oxytocin-secreting neurons in the supraoptic and the paraventricular nuclei of the hypothala-
mus and elicits a marked increase in plasma oxytocin levels in conscious rats. Here, I review the roles of 
the CGRP family in the CNS.
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activation of the CRLR/RAMP1 and AM22-52 blocked 
the activation of the CRLR/RAMP2 and CRLR/
RAMP312）.
Many previous studies have shown that centrally 
administered neuropeptides activated various areas 
in brain and affected physiological and pathophysiolog-
ical functions. Our previous studies showed that cen-
tral administration of AM family （AM, AM2 and AM5） 
induced the expression of the c-fos gene in the supra-
optic （SON） and the paraventricular nuclei （PVN） of 
the hypothalamus and elicited the marked increase of 
plasma oxytocin levels in conscious rats 13～15）. In this 
review, I focus on （1） the distribution, （2） receptor, 
and （3） physiological roles of CGRP family in the 
CNS.
Calcitonin gene-related peptide （CGRP）
Distribution and synthesis of CGRP
CGRP is a 37-amino acid peptide （Fig. 1） and is 
produced by alternative splicing of RNA from the cal-
citonin gene 16,17）. CGRP is principally located in unmy-
elinated sensory C-fibers and myelinated Ad-fibers of 
peripheral nerves 18～20）. CGRP is co-located with sub-
stance P in C-fibers 20）. In the periphery, CGRP is also 
localized in the adrenal gland, pancreas and nerves at 
the adventitial-medial border of coronary blood ves-
sels 17,21,22） （Table 1）. In the CNS, the CGRP mRNAs 
were also distributed in the peripeduncular nucleus 
（PP）, nucleus of oculomotor nerve, parabrachial nuclei 
（PBN）, nucleus of trigeminal nerve, superior olivary 
nucleus, motor nucleus of facial nerve, nucleus ambig-
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Fig. 1　Structure of CGRP family
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uus, nucleus of hypoglossal nerve 23） （Table 2）. In 
immunohistochemistry studies, CGRP-like immunore-
activity （LI） was localized in the olfactory bulb （OB）, 
central nucleus of the amygdala （CeA）, PVN, lateral 
hypothalamic area （LHA）, dorsomedial hypothalamic 
nucleus （DMH）, ventromedial nucleus of hypothala-
mus （VMH）, arcuate nucleus （Arc）, superior olivary 
nucleus, parabigeminal nucleus, superior colliculus, 
vestibular nuclei, posterior agranular insular area 
（INS）, PP, PBN, area postrema （AP）, nuclei of soli-
tary tract （NTS）, nucleus of hypoglossal nerve17,24）. 
As these areas are involved in nociception, feeding, 
stress, emotion and autonomic function （Table 2）, 
CGRP may involve in these physiological functions.
Distribution of CGRP receptor
Some previous studies showed that mRNAs encod-
ing the CR and CRLR gene products are expressed in 
many tissues such as heart, spleen, spinal cord, and 
predominantly in the lungs 25,26）. In the CNS, the CRLR 
mRNAs are expressed in the caudate putamen and 
amygdala 27,28）. As well as CRLR, mRNAs encoding 
RAMPs are expressed in many tissues, including 
heart, skeletal muscle, gastrointestinal tract, spinal 
cord, pituitary, adrenal, and thyroid glands 10）. CGRP 
activates the combination of CRLR with RAMP1. Oli-
ver et al. showed the distribution of RAMP1 mRNAs 
in the rat CNS in detail 28）. RAMP1 mRNAs was wide-
spread in the CNS, especially abundantly expressed in 
the olfactory tubercles, piriform cortex, nucleus 
accumbens, caudate putamen, cortex, and amygdala 28）.
Table 1　Distribution of CGRP family gene in tissues
CGRP AM AM2 AM5 Amylin
brain ＋ ＋
pituitary ＋ ＋ ＋
heart ＋
lung ＋ ＋
adrenal gland ＋ ＋ ＋
kidney ＋ ＋
liver ＋
bone ＋
pancreas ＋ ＋ ＋ ＋
esophagus ＋
stomach ＋ ＋ ＋
small intestine ＋ ＋ ＋
large intestine ＋ ＋ ＋
rectum ＋
mesentery ＋
spleen ＋ ＋ ＋
thymus ＋ ＋ ＋
submaxirally ＋ ＋
testis ＋
ovary ＋ ＋
uterus ＋
References 17 37 4, 5 6 92, 93, 116, 117
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Table 2　Distribution of CGRP family in the CNS
physiological role
CGRP
mRNA
CGRP
-LI
AM
-LI
AM2
-LI
amylin
-LI
Telencephalon
bed nucleus of stria terminalis fear, feeding, social behavior, pain ＋ ＋ ＋
central amygdaloid nucleus emotion, memory, stress ＋ ＋ ＋
globus pallidus motivation, voluntary movement ＋ ＋
hippocampus memory, learning ＋ ＋
innominate substance memory ＋
medial septal nucleus memory ＋ ＋ ＋
olfactory bulb （OB） odor system ＋ ＋ ＋
posterior agranular insular area （INS） emotion, addiction, taste ＋
striatum motor, learning, memory ＋
Diencephalon
arcuate nucleus （Arc） feeding ＋ ＋ ＋
circularis nucleus osomosencer ＋
dorsomedial nucleus （DMH） feeding, drinking, body-weight regulation, circadian activity ＋ ＋ ＋
habenular nucleus addiction, emotion ＋ ＋
lateral hypothalamic area （LHA） feeding ＋ ＋
mammillary body memory ＋ ＋
median preoptic nucleus （MnPO） drinking, osomosenser ＋
paraventricular nucleus （PVN） feeding, stress, pain, social behavior, autonomic system ＋ ＋ ＋ ＋
preoptic nucleus
sexual and parental behavior, sleep-awake cycle, 
thermoregulation
＋ ＋
suprachiasmatic nucleus circadian rhythm ＋
supraoptic nucleus （SON） neuroendocrine system ＋ ＋ ＋
vascular organ of the lamina terminalis 
（OVLT） 
drinking, osomosenser ＋
ventromedial nucleus of hypothalamus 
（VMH） 
feeding ＋ ＋
Mesencephalon
cochlear nuclei auditory system ＋ ＋
cuneate nucleus pain, somatosensory system ＋ ＋ ＋
interfascicular nucleus reward system, motivation, cognition, addiction ＋
nucleus of oculomotor nerve origin of oculomotor nerve ＋ ＋ ＋ ＋
parabigeminal nucleus vision system ＋
peripeduncular nucleus （PP） sexual behavior, milk ejection ＋ ＋
superior colliculus somatosensory sytem, eye movements, auditory system ＋ ＋ ＋
Pons
area postrema （AP） vomiting centre, cardiovascular system, feeding, metabolism ＋ ＋ ＋
nucleus of facial nerve origin of facial nerve ＋ ＋ ＋
nucleus of trigeminal nerve origin of trigeminal nerve ＋ ＋ ＋ ＋
parabrachial nuclei （PBN） nociception, feeding, taste ＋ ＋
pontine nuclei motor system ＋ ＋
red nucleus motor system ＋ ＋
substantia nigra reward system, motor system ＋ ＋ ＋
superior olivary nucleus auditory system ＋ ＋ ＋ ＋
trapezoid body auditory system ＋ ＋
Cerebellum
cerebellar nuclei motor system ＋
Myencephalon
inferior olivary nucleus motor system, sensory system ＋
locus coeruleus nucleus （LC） sleep-wake cycle, memory, attetion, emotion, stress ＋ ＋
nuclei of solitary tract （NTS） pain, taste, intestinal motility, cardiovascular system, stress ＋ ＋ ＋
nucleus ambiguus speech ＋ ＋ ＋ ＋
nucleus of hypoglossal nerve origin of hypoglossal nerve ＋ ＋ ＋
vestibular nuclei vestibular system ＋ ＋ ＋
References 23 17, 24 39, 40 75 92
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Physiological role of CGRP in the CNS
Previous studies have shown effects of centrally 
administered CGRP on food intake and intestinal 
motility. Centrally administered CGRP suppresses food 
intake in food-deprived rats 29,30）. Although peripheral-
ly administered CGRP decreases food intake in rat 
and mice 29,31）, the effects of peripheral administered 
CGRP were less effective than those of centrally 
administered CGRP in rats 29）. Krahn et al. also 
showed that centrally administered CGRP decreased 
saccharin intake by one-bottle conditioned aversion 
test, and suggested that the centrally administered 
CGRP-induced food suppression involves an aversive 
mechanism32）. While, centrally administered CGRP 
increases food intake and rumination, and decreases 
the frequency of forestomach motility in the sheep33）. 
In goldfish, centrally administered CGRP significantly 
decreases the food intake 34）. The effects of centrally 
administered CGRP may be different among the spe-
cies.
Centrally administered CGRP significantly increases 
the mean arterial pressure （MAP） and the heart rate 
（HR） in rats 35）. The effects of CGRP on MAP and HR 
are attenuated by pretreatment with CGRP receptor 
antagonist 35）. The effects of CGRP on increasing MAP 
are inhibited by pretreatment with alpha adrenorecep-
tor-blocker. The effects of CGRP on increasing HR 
are suppressed by pretreatment with alpha- and 
beta-adrenoreceptor-blocker. Moreover, the effects of 
CGRP on increasing MAP and HR are suppressed by 
the chemical sympathectomy. Centrally administered 
CGRP also increased plasma adrenaline and noradren-
aline 35）. Central administered CGRP may stimulate 
sympathetic nervous system and increase MAP and 
HR.
As described above, some previous studies showed 
the central effects of CGRP on feeding and cardiovas-
cular function. In immunohistochemistry study for 
CGRP, CGRP-LI cells were found in the OB, Arc, bed 
nucleus of stria terminalis, DMH, LHA, medial septal 
nucleus, PVN, preoptic nucleus, cuneate nucleus, INS, 
PBN, AP and NTS （Table 2）. These areas are 
involved in feeding, neuroendocrine system, sleep-
awake cycle, thermoregulation, cardiovascular func-
tion, pain, emotion, and memory. Beside feeding and 
cardiovascular function, the further study may clarify 
the physiological role of CGRP in the nociception, neu-
roendocrine system, sleep-awake cycle, thermoregula-
tion, emotion and memory.
Adrenomedullin （AM）
Distribution and synthesis of AM
AM is a 52-amino acid neuropeptide （Fig. 1） that 
was originally isolated from tissue extracts of human 
pheochromocytoma36）. AM was widely distributed in 
peripheral organs and the CNS 37～42） （Table 1）. In 
peripheral organs, AM mRNAs were expressed in 
adrenal glands, lung, kidney, heart, spleen, duodenum, 
and submandibular glands 37） （Table 1）. A large amount 
of AM is synthesized and secreted from the endothelial 
cells and vascular smooth muscle cells 38,43～45）. Some 
previous studies showed that the plasma AM levels 
increased in the cardiovascular disease, including 
hypertension, chronic renal failure, congestive heart 
failure, stroke, and septic shock 46～50）. In the CNS, at 
first, AM-LI cells were found in the SON, PVN, and 
circularis nucleus in rats 40,41）. Serrano et al. investigat-
ed the distribution of AM-LI cells in rats in detail 39）. 
AM-LI cells were found in multipolar neurons and 
pyramidal cells in the layers IV-VI of the cerebral 
cortex, mitral cells and granule cells of the olfactory 
bulb, caudate putamen, globus pallidus, amygdala, bed 
nucleus of the stria terminalis, LHA, DMH, PVN, Arc, 
medial and lateral habenular nuclei, cuneate nucleus, 
interfascicular nucleus, reticulate and lateralis of the 
substantia nigra, nucleus of oculomotor nerve, superior 
colliculus, lateral and medial superior olivary nucleus, 
vestibular nuclei, locus coeruleus nucleus （LC）, and 
AP in rats 39）. AM-LI cells were co-localized with oxy-
tocin （OXT） and arginine vasopressin （AVP） in the 
SON and PVN in rats 41）. In human, AM-LI cells were 
found in the SON and PVN 42）. These areas are 
involved with cardiovascular system, feeding, social 
recognition, emotion, reward system, learning, water 
balance, and autonomic function （Table 2）.
Distribution of AM receptor
AM activates the combination of CRLR with 
RAMP2 and with RAMP3. Oliver et al. showed the 
distribution of RAMP2 and PAMP3 mRNAs in the rat 
CNS in detail 28）. RAMP2 mRNAs are expressed in the 
olfactory tubercles, the cortex, hippocampus, SON, 
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PVN, Arc, VMH, DMH, amygdala, nucleus of hypo-
glossal nerve, paragigantocellular reticular nucleus, 
and ventrolateral medulla 28,51）. RAMP3 mRNAs are 
expressed in the olfactory tubercles, piriform cortex, 
nucleus accumbens, hippocampus, habenula nucleus, 
PVN, Arc, VMH, DMH, and granule cell layer of the 
cerebellum28）.
Physiological role of AM in the CNS
The expression of the c-fos protein has been widely 
used to detect the neuronal activity in the CNS52）. 
Some previous studies investigated the central effects 
of CGRP family using c-fos protein activity. After 
intracerebroventricular （icv） administration of AM, 
Fos-LI cells were found in various areas of brain in 
rats, including the SON, PVN, VMH, CeA, lateral 
habenular nucleus, PBN, LC, AP, NTS, and rostal ven-
trolateral medulla （RVLM） in rats 53,54）. Moreover, 
AM-induced Fos expression was attenuated by pre-
treatment with a CGRP receptor antagonist（CGRP8-37）
in rats 54）. Centrally administered AM activated OXT-
secreting neurons in the SON and PVN, and also 
increased plasma OXT level in rats 55,56）. Fos-LI cells 
were co-localized with neuronal nitric oxide synthase 
（nNOS）-LI neurons in the SON, PVN, NTS, and 
nucleus paragigantocelluaris lateralis after icv admin-
istration of AM in rats 54）. AM-induced Fos expres-
sions in nNOS-LI cells were attenuated by pretreat-
ment with CGRP receptor antagonist 54）.
I focused on neurohypophysial hormone, AVP and 
OXT. AVP and OXT are nine amino acid neuropep-
tides, and the structure of AVP differs from that of 
OXT by only 2 amino acids. Both peptides are synthe-
sized in the SON and PVN that terminate their axons 
in the posterior pituitary 57）. AVP plays a role in water 
homeostasis and cardiovascular regulation, and also 
controls osmolality and blood pressure. OXT is well 
known for its roles in reproduction, especially during 
and after childbirth. OXT is also involved in several 
physiological functions, such as antinociception, anxi-
ety, feeding, social recognition and stress responses 58～
62）. Central administration of AM also activates OXT-
secreting neurons 14,55） and increases plasma OXT lev-
els in rats 55）. While, icv administration of AM had no 
significant effect on the plasma concentrations of AVP 
in rats 63） and sheep 64）. Furthermore, AM was reported 
to inhibit the release of AVP that is normally evoked 
by hypertonic and hypovolemic stimulation in rats 63）.
As well as CGRP, centrally administered AM inhib-
its feeding in rats 65）. Pretreatment with a CGRP 
receptor antagonist （CGRP8-37） attenuates this AM-
induced anorexia 65）. After icv administration of AM, 
Fos-LI cells were found in the PVN, VMH, and 
PBN53,54）. As these areas are related to the central 
regulation of feeding behavior, centrally administered 
AM may activate neurons in these areas and inhibit 
food intake.
Water intake is controlled by body fluid and osmo-
lality. In general, when we investigate the effects of 
neuropeptides on water intake, we used water 
deprived model, angiotensin II （AII） induced water-
intake model, and polyethylene glycol induced isotonic 
hypovolemia model 66～68）. In water deprived rats, cen-
trally administered AM significantly decreases the 
water intake 69,70）. Centrally administered AM signifi-
cantly decreases AII-induced water intake 70）. Central-
ly administered AM also significantly decreased the 
water intake in hyperosmotic stimuli in rats 70）. More-
over, centrally administered AM inhibits salt appetite 
in rats 71）. These results suggested that AM may 
involve in the regulation of body fluid in the CNS.
As AM is produced in the vascular smooth muscle, 
AM is considered a potent vasodilator Peripheral 
administration of AM increased heart rate, decreases 
arterial blood pressure, and inhibits urine flow72～75）. 
Centrally administered AM as well as peripherally 
administered, has a cardiovascular action. Centrally 
administered AM increases the MAP and the HR in 
rats 35,74～76） and in rabbit 77）. These effects of AM on 
MAP and HR are significantly suppressed by pre-
treatment with an AM receptor antagonist （AM22-52） 
or a CGRP receptor antagonist （CGRP8-37） in rat
76）. In 
sheep, although peripherally administered AM 
decreases MAP and increases HR, centrally adminis-
tered AM does not change either MAP or HR64）.
As described above, some previous studies showed 
the central effects of AM on feeding, drinking, neuro-
endocrine system, and cardiovascular function. In 
immunohistochemistry study for AM, AM-LI cells 
were found in the OB, Arc, bed nucleus of stria termi-
nalis, DMH, LHA, medial septal nucleus, PVN, SON, 
innominate substance, cuneate nucleus, habenular 
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nucleus, mammillary body, AP and LC （Table 2）. 
These areas are involved in feeding, neuroendocrine 
system, cardiovascular function, pain, addiction, emo-
tion, and memory. Besides feeding, neuroendocrine 
system, and cardiovascular function, the further study 
may clarify the physiological role of AM in pain, 
addiction, emotion, and memory.
Adrenomedullin 2 （AM2）
Distribution and synthesis of AM2
A 47-amino acid neuropeptide （Fig. 1）, AM2 was 
first isolated from pufferfish 3,5） and later from mam-
mals 4,5） by the bioinformatics technique. AM2 is identi-
cal to intermedin, which was discovered by Roh et 
al. 5）. AM2 is also widely distributed in peripheral 
organs and the CNS （Table 1）. AM2 mRNAs are 
expressed in the submaxillary gland, kidney, stomach 
and mesentery, pituitary, lung, pancreas, intestines, 
spleen, thymus and ovary in mice 4） （Table 1）. In 
human, AM2 mRNAs are expressed in the esophagus, 
stomach, jejunum, ileum, ileocecum, ascending colon, 
transverse colon, descending colon, and rectum 5） 
（Table 1）. AM2 was also detected in the lung, heart, 
stomach kidney cerebellum, pituitary, brain stem, and 
hypothalamus in rats 69）. We showed that AM2-LI 
were observed in the intermediate lobe of pituitary, 
vascular organ of lamina terminalis （OVLT）, median 
preoptic nucleus （MnPO）, VMH, SON, PVN, Arc, LC, 
AP, NTS, and nucleus ambiguus in rats 78）. These 
areas are involved with cardiovascular system, feed-
ing, sleep-awake cycle, water balance, and autonomic 
function （Table 2）. Moreover, we showed that after 
salt loading, AM2-LI cells were significantly visual-
ized stronger than those of control rats in the SON 
and the magnocellular parts of the PVN78）. Colchicine 
treatment is known to block axonal transport, result-
ing in neuropeptide accumulation in the cell body78～80）. 
After colchicine treatment, AM2-LI cells were signifi-
cantly visualized stronger than those of control rats in 
the SON, the magnocellular parts of the PVN and 
LC 78）. As neurons in the SON and PVN terminate 
their axons to the posterior pituitary （PP）, produced 
AM2 in the SON and PVN may axon-transport to PP 
and secrete from PP to circulation in rats. According-
ly, these findings in salt loading and colchicine study 
indicated that AM2 was produced in the SON and 
PVN, and mainly secreted from posterior pituitary by 
the axonal transports.
Distribution of AM2 receptor
The information about receptor of AM2 has not 
been known in detail. As the induction of c-fos gene 
after icv administration of AM2 were attenuated by 
pretreatment with CGRP and/or AM receptor antago-
nists 13,14）, AM2 activates the combination of CRLR 
with RAMPs. We showed that the induction of c-fos 
gene after icv administration of AM were attenuated 
by pretreatment with either the CGRP or AM recep-
tor antagonists and completely blocked by pretreat-
ment with both the CGRP and AM receptor antago-
nists 14）. We also showed that the induction of c-fos 
gene after icv administration of AM2 was attenuated 
by pretreatment with either the CGRP or AM recep-
tor antagonists, as well as AM. Interestingly, unlike 
AM, the induction of c-fos gene after icv administra-
tion of AM2 was attenuated, not completely blocked, 
by pretreatment with both the CGRP and AM recep-
tor antagonists 14）. Therefore, AM2 may activate neu-
rons via other pathway directly or indirectly, includ-
ing unknown receptor.
Physiological role of AM2 in the CNS
As well as AM, icv administration of AM2, Fos-LI 
cells were found in the SON, PVN, CeA, VMH, LC, 
AP, and NTS （Fig. 2）13）. Centrally administered AM2 
also induced the expression of c-fos gene in the SON 
and PVN, and this induction was significantly reduced 
by pretreatment with both the CGRP （CGRP8-37 3 
nmol） and AM （AM22-52 27 nmol） receptor antago-
nists （Fig. 3）13,14）. Icv administration of AM2 also acti-
vated OXT-secreting neurons and elevated circulating 
OXT levels in rats 13,14）. I also found a few AVP-LI 
cells in the SON and the PVN that exhibited nuclear 
Fos-LI after icv administration of AM2 and a small 
increase in the plasma concentration of AVP at 30 min 
after icv administration of AM2, unlike AM13,15）. The 
activation of AVP neurons by centrally administered 
AM2 is different from the actions of centrally adminis-
tered AM. Although the effects of centrally adminis-
tered AM2 were similar to those of AM13,14,55,65,70,71,74,75） 
and were mediated by both AM and CGRP recep-
tors 81）, I also showed that centrally administered 
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effects of AM2 （1 nmol） were stronger than those of 
AM （1 nmol） in the expression of the c-fos gene in 
the SON and PVN （Fig. 3 A and B）, plasma OXT 
level, and blood pressure （Fig. 3 C） in rats 14）. The 
combination of AM and CGRP receptor blockade com-
pletely inhibited c-fos gene expression after centrally 
administered AM, while there was an incomplete inhi-
bition after centrally administration of AM214）.
Centrally administered AM2 inhibits food intake in 
rats in the same manner as it does when given 
peripherally 69）. We showed that Fos-LI cells were 
found in the PVN and VMH after centrally adminis-
tration of AM2 in rats 13）. The VMH and PVN are 
related to the central regulation of feeding behavior. 
Especially, the VMH is called a satiety center, and I 
presume that the activation of the VMH may inhibit 
the feeding behavior after central administration of 
AM2. In the effect for water drinking, as well as AM, 
vehicle AM2 (2 nmol)
E
G
F
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VMH
LC
AP
PVN
SON
A
C
K L
JI
B
D
NTS
OC OC
3V3V
3V3V
4V4V
Fig. 2
Photomicrographs showing changes in Fos- like 
immunoreactivity in the supraoptic nucleus （SON） 
（A and B）, the paraventricular nucleus （PVN） （C 
and D）, the central nucleus of the amygdala （CeA） 
（E and F）, the ventromedial nucleus of the hypo-
thalamus （VMH） （G and H）, the locus coeruleus 
（LC） （I and J）, and the area postrema （AP） and 
the nucleus of the solitary tract （NTS） （K and L）. 
OC, optic chiasma；3V, third ventricle；4V, fourth 
ventricle. Bars indicate 100 m. Modified with permis-
sion from Fig. 7 in ref. ［13］．
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centrally administered AM2 significantly decreases 
water intake in water-deprived rats 69,70）.
Peripherally administered AM2 decreases MAP, 
inhibits urine flow, increases renal sympathetic nerve 
activity as well as AM 5,72 ,73）. By all accounts, the 
effects of the AM and AM2 are qualitatively and 
quantitatively similar 4,5,72,73）. However, the actions of 
AM or AM2 given centrally is quite different from 
their actions when given peripherally. Unlike periph-
eral administration, centrally administered AM2 
increased MAP and HR 69）. I showed that centrally 
administered AM and AM2 increased BP and HR in 
rats （Fig. 3 C and D）14）. The effects of AM2 on MAP 
were stronger and longer than those of AM 14）. I 
showed that icv administration of AM2 activated neu-
rons in the NTS in rats （Fig. 2）13）. Recently, Li et al. 
showed that microinjection of AM2 into the NTS 
increased the MAP and the sympathetic outflow via 
cAMP/PKA signaling pathway in rats 82）. Centrally 
administered AM2 may be involved in the central reg-
ulation of the cardiovascular system via the NTS.
In immunohistochemistry study for AM2, AM2-LI 
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Fig. 3
Effects of intracerebroventricular （icv） injection of saline （vehicle）, AM （1 nmol/rat）, or adrenomedullin 2 （AM2） （1 nmol/
rat） on c-fos transcript prevalence in the supraoptic nucleus （SON） （A） and the paraventricular nucleus （PVN） （B） 
10 min after pretreatment with AM antagonist （AM22-52 27 nmol/rat） or/and CGRP antagonist （CGRP8-37 3 nmol/rat）. Rats 
were decapitated 30 min after icv injection of AM （1 nmol/rat）, AM2 （1 nmol/rat） or vehicle. Values represent the mean±
SEM （n＝6）. ＊＊ P＜0.01, compared with vehicle-administered rats；##P＜0.01, compared with AM-administered rats. ＄＄P＜
0.01 and ＄P＜0.05, compared with AM22-52＋CGRP8-37＋AM2-administered rats. Time courses of changes in mean arterial 
pressure （MAP） （C） and heart rate （HR） （D） after icv injection of vehicle, AM （1 nmol/rat） or AM 2 （0.2 and 1 nmol/
rat） in urethane-anesthetized rats. Values represent the mean±S.E.M. （n＝6）. ＊ P＜0.05 and ＊＊ P＜0.01, compared with 
vehicle-administered rats. #P＜0.05 and##P＜0.01, compared with AM-administered rats. ＄P＜0.05, compared with AM2 
0.2 nmol-administered rats. Modified with permission from Fig. 1 and Fig. 5 in ref. ［14］．
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cells were found in the Arc, MnPO, OVLT, PVN, SON, 
VMH, AP, LC, and NTS （Table 2）. These areas are 
involved in feeding, drinking, neuroendocrine system, 
cardiovascular function, memory, emotion, stress, 
sleep-awake cycle. As described above, some previous 
studies showed the central effects of AM2 on feeding, 
drinking, neuroendocrine system, and cardiovascular 
function. The further study may clarify the physiologi-
cal role of AM2 in stress, sleep-awake cycle, emotion, 
and memory.
Adrenomedullin 5 （AM）
Distribution and synthesis of AM5
AM5 is a 52-amino acid neuropeptide （Fig. 1）. 
Takei and colleagues identified five AMs （AM1-5） in 
teleost fish, and they form an independent subfami-
ly 3,5）. They searched the orthologs of the AMs in the 
genome and established sequence tag databases and 
showed that AM, AM2, and AM5 in mammals are 
respectively identical to AM1, AM2, and AM5 in tele-
ost fish 6,83）. In the pig, AM5 mRNAs are expressed in 
the spleen and thymus 84）. Although AM5 was identi-
fied from pig, ox, sheep, horse, dog, cat, AM5 could 
not be identified in rodents and AM5-like sequence 
exists in human84）. However, we showed that central 
administered porcine AM5 activated OXT-secreting 
neurons in the SON and PVN in rats. These results 
indicated that porcine AM5 activate OXT secreting 
neuron in the hypothalamus partly via AM/CGRP 
receptor or unknown receptor system for AM5 in 
rats.
Distribution of AM5 receptor
The information about receptor of AM5 has not 
been known in detail. As the induction of c-fos gene 
after icv administration of AM5 were attenuated by 
pretreatment with CGRP and/or AM receptor antago-
nists 13,14）, AM5 activates the combination of CRLR 
with RAMPs. We showed that the induction of c-fos 
gene after icv administration of AM were attenuated 
by pretreatment with either the CGRP or AM recep-
tor antagonists and completely blocked by pretreat-
ment with both the CGRP and AM receptor antago-
nists 14）. We also showed that the induction of c-fos 
gene after icv administration of AM5 was attenuated 
by pretreatment with either the CGRP or AM recep-
tor antagonists, as well as AM. Interestingly, unlike 
AM, the induction of c-fos gene after icv administra-
tion of AM5 was attenuated, not completely blocked, 
by pretreatment with both the CGRP and AM recep-
tor antagonists 14）. Therefore, AM5 may activate neu-
rons via other pathway directly or indirectly, includ-
ing unknown receptor, as well as AM2.
Physiological role of AM5 in the CNS
After icv administration of AM5, Fos-LI cells were 
found in the CeA, MnPO, SON, PVN, VMH, Arc, LC, 
AP, and NTS15）. As these nuclei are related with emo-
tion, memory, drinking, feeding, stress, sleep-awake 
cycle, vomiting, pain, and cardiovascular system, 
AM5 may have a role in these physiological functions. 
As well as AM and AM2, central administration of 
AM5 activates OXT-secreting neurons and increases 
plasma OXT levels in rats 15）. Centrally administered 
AM5 induces the expression of c-fos gene in the SON 
and the PVN, and this induction was significantly 
reduced by pretreatment with both the CGRP 
（CGRP8-37） and AM （AM22-52） receptor antagonists
15）. 
Therefore, I presume that central administered 
AM5 may activate OXT-secreting neurons in the 
SON and PVN partly through the CGRP and/or AM 
receptor, as well as AM2 . The further study is 
required to explore the possibility that unknown spe-
cific receptors for AM5 and/or AM2 may exist in the 
CNS.
Centrally administered AM5, as well as AM and 
AM2, increases BP and HR in rats 6）, but the effects of 
centrally administered AM5 were larger and shorter-
lasting than those of centrally administered AM 6）. 
The effects of centrally administered AM2 were larg-
er and longer than those of centrally administered 
AM （Fig. 3 C and D）. Therefore, the central effects of 
AM2 and AM5 were different from those of AM on 
MAP and HR in potency and duration in rats 6,14）. Cen-
trally administered AM2 and AM5 may increase MAP 
and HR partially via unknown specific receptors for 
AM2 and AM5 in the CNS.
Amylin
Distribution and synthesis of amylin
Amylin, also called islet amyloid polypeptide 
（IAPP）, is a 37-amino acid peptide that was originally 
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isolated from pancreatic amyloid deposit in diabetes 
（Fig. 1）85,86）. It is produced by pancreatic b-cells 87,88）, 
and secreted with insulin by glucose stimulation 89～91）. 
Amylin mRNAs are expressed in the pancreas, stom-
ach, duodenum, jejunum, ileum, colon, dorsal root gan-
glion, and trigeminal ganglion 92～94）. Unlike other mem-
bers of the CGRP family, at first amylin mRNAs had 
not been distributed in the CNS, probably due to 
technical problem94）. However, Amylin-LI cells were 
found in the dorsal root ganglion, jugular nodose gan-
glion, and trigeminal ganglion, olfactory bulb （OB）, 
preoptic nucleus, the bed nucleus of the stria termina-
lis, suprachiasmatic nucleus, PVN, SON, DMH, VMH, 
mammillary body of the hypothalamus, habenular 
nucleus, the substantia nigra, red nucleus, pontine 
nuclei, inferior olivary nucleus, NTS, and cuneate 
nucleus, and vestibular nuclei 95,96）. These areas are 
involved with feeding, circadian rhythm, addiction, 
emotion, water balance, pain, reproductive behavior, 
stress, learning, motor system and autonomic function 
（Table 2）.
Distribution of amylin receptor
Amylin has three receptors, amylin receptor 1-3 
（AMY1-3）, which is combination of CR with RAMP 
1-3 9,97）. As described above, RAMP1-3 is fairly wide-
spread in the CNS. CR mRNA is distributed in the 
nucleus accumbens, preoptic area, suprachiasmatic 
nucleus, PVN, DMH, VMH, Arc, amygdala, LC, and 
raphe nucleus in rats 98）.
Physiological role of amylin in the CNS
Peripherally administered amylin induced Fos 
expression in the AP, NTS, anterior hypothalamic 
area, and dorsomedial hypothalamic nucleus in mice 99）. 
To the best of our knowledge, no previous study has 
examined Fos-LI expression after centrally adminis-
tered amylin. After icv administration of CGRP, Fos-
LI cells were found in the preoptic area and PVN in 
rats 99）. To elucidate the central mechanism of CGRP 
family, I should investigate where centrally adminis-
tered CGRP and amylin induce Fos-LI expressions in 
the CNS.
Amylin is known to inhibit basal and insulin-stimu-
lated periphery glucose uptake and glycogen synthe-
sis 100,101）. Some previous studies reported that periph-
erally administered amylin decreases food intake in 
rats 102～105）. This amylin-induced anorexia was signifi-
cantly abolished by pretreatment with CGRP receptor 
antagonist （CGRP8-37） in rats
106）. Icv administration of 
amylin decreases food intake in rats 107～109） and 
mice 96,110）. Icv administration of amylin also inhibits 
gastric acid secretion in rats 111）. Centrally adminis-
tered amylin decreases gastric emptying and intesti-
nal transit in rats 112）. Intrahypothalamic administration 
of amylin also decreased food intake in rats 103）. After 
intrahypothalamic administration of amylin, concentra-
tions of dopamine, tryptophan, and their metabolites 
were significantly increased in the hypothalamus, cor-
pus striatum and nucleus accumbens in rats 103）. These 
results indicated that intrahypothalamic administra-
tion of amylin inhibited feeding by acting directly on 
hypothalamic neurons to alter metabolism.
Peripherally administered amylin decreases MAP 
and increases HR in rats 113,114）. Icv administration of 
amylin increases HR, and O2 consumption rate in 
anesthetized rats 115）. These effects of centrally admin-
istered amylin were eliminated by the electrolytic 
ablation of the AP115）. AP is known as the vomiting 
center and involve in autonomic nervous system. I 
presume that centrally administered amylin may 
increase MAP via AP/NTS and be involved in the 
central regulation of the cardiovascular system.
In immunohistochemistry study for amylin, amylin-
LI cells were found in the OB, bed nucleus of stria 
terminalis, amygdala, PVN, preoptic nucleus, suprachi-
asmatic nucleus, SON, VMH, and NTS （Table 2）. 
These areas are involved in feeding, neuroendocrine 
system, cardiovascular function, circadian rhythm, 
memory , emot ion , stress , and pain . As above 
described, some previous studies showed the central 
effects of amylin on feeding and cardiovascular func-
tion. The further study may clarify the physiological 
role of amylin in stress, neuroendocrine system, circa-
dian rhythm, memory, emotion, stress, and pain.
CONCLUSION
Many neuropeptides have been discovered. Many 
studies showed physiological and pathophysiological 
role of these neuropeptides. Some neuropeptides, such 
as human atrial natriuretic peptide （hANP）, brain 
natriuretic peptide （BNP）, and orexin receptor antag-
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onist, are used as medical drugs or diagnosis. I have 
investigated the central effects of neuropeptides and 
reported my results obtained in some previous stud-
ies. Lots of studies about the peripherally effects of 
CGRP family were reported and some clinical trials 
for CGRP, AM and amylin are ongoing. However, the 
mechanism for central effects of CGRP family is 
unknown. Although CGRP family is considered that 
they cannot pass through the blood brain barrier, 
they and their receptor exist in the CNS and have 
some effects when it is administered centrally. In this 
review, I summarized that central administered CGRP 
family have some effects on autonomic function （Fig. 
4）. There is a possibility that unknown specific recep-
tors for AM2 and/or AM5 may exist in the CNS. I 
anticipate that further studies can clarify the mecha-
nism of the central effects of CGRP family, including 
exploration of unknown receptors in the CNS.
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Fig. 4
Schema of central effects of CGRP family in sagittal section of diencephalon and brain stem. CGRP 
family activates neurons in the central nervous system. They activated neurons in the hypothala-
mus and medulla, which is related with appetite, water balance, sleep-awake cycle, learning, and 
cardiovascular system. They may involve in the regulation of feeding, drinking, cardiovascular 
system, and neuroendocrine system. Arc, arcuate nucleus；AP, area postrema；LC, locus coerule-
us nucleus；LHA, lateral hypothalamic area；MnPO, median preoptic nucleus；NTS, nuclei of sol-
itary tract；OVLT, vascular organ of lamina terminalis；OB, olfactory bulb；POA, preoptic 
area；PP, posterior pituitary；PVN, paraventricular nucleus；RN, raphe nucleus；SFO, subforni-
cal organ；SON, supraoptic nucleus；VMH, ventromedial nucleus of the hypothalamus.
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